Short answer
Twist Bioscience Corp (TWST) filed its Q1 2026 10-Q quarterly report on May 4, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $111M (up 19.3% year over year) with net income of −$44M.
Q1 2026 key financials · XBRL
- Revenue
- $111M
- +19.3% YoY · +6.8% QoQ
- Net income
- −$44M
- −11.9% YoY · −44.3% QoQ
- Operating margin
- -41.4%
- EPS (diluted)
- −$0.71
- −7.6% YoY · −42.0% QoQ
Source: XBRL data from the Twist Bioscience Corp (TWST) Q1 2026 10-Q on SEC EDGAR. USD.
Twist Bioscience Corp Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $110.7M, up 19% YoY from $92.8M, driven by DNA synthesis and protein solutions up 28%
- Gross margin 51.6% vs 49.6% YoY, up 2.0 percentage points
- Best product line DNA synthesis and protein solutions, $53.3M, up 28%; NGS applications $57.4M, up 12%
- Cash, equivalents and short-term investments $171.7M; operating cash use $42.4M vs $34.4M YoY
- $33.8M Invenra commitment, including $5.0M cash; SG&A expected to moderate in fiscal 2026 second half
Risk Factors
- No risk-factors section provided; excerpt contains Items 2–6 only
- Insider trading-plan risk: Chief Legal Officer may sell up to 56,820 shares by February 26, 2027
- Regulatory compliance disclosure: Rule 10b5-1 plan adopted February 17, 2026
- No liquidity, debt, currency, competitive, operational, or legal risks disclosed in provided text
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Twist Bioscience Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.